Result from Glanzmann Thrombasthenia Therapy Clinical Trial

Results from a phase 2 clinical trial of an investigational therapy for the treatment for Glanzmann thrombasthenia were announced by Hemab Therapeutics.  The therapy, Sutacimig, is a bispecific antibody that is delivered subcutaneously and is the first-ever prophylactic treatment for the ultra-rare bleeding disorder.

Source: National Bleeding Disorders Foundation, NBDF Notes, December 2025